The use of bisphosphonates in pediatrics
- PMID: 25376487
- DOI: 10.1159/000365889
The use of bisphosphonates in pediatrics
Abstract
Bisphosphonates are widely used for the prevention and treatment of osteoporosis in adulthood. In the last years, bisphosphonates have been increasingly used in pediatric patients for the treatment of a growing number of disorders associated with osteoporosis, resistant hypercalcemia or heterotopic calcifications. The use of bisphosphonates in pediatric patients has been proven safe; however, the risk of potential severe consequences into adulthood should be kept in mind. Well-defined criteria for bisphosphonates treatment in pediatric patients are not specified, therefore an accurate selection of patients who could benefit from bisphosphonates is mandatory. A strict follow-up of pediatric patients receiving long-term bisphosphonate therapy is strongly recommended. The purpose of this mini review is to provide a summary of current knowledge on some main general aspects of the structure, mechanisms of action, pharmacokinetics, and bioavailability of bisphosphonates, and to focus on the latest advances of bisphosphonate treatment in pediatric patients. Particular attention has been paid to the common and potential adverse effects of bisphosphonate treatment, and some suggestions concerning the clinical approach and general measures for bisphosphonate treatment in pediatric patients are reported.
2014 S. Karger AG, Basel
Similar articles
-
Long-term use of bisphosphonates in osteoporosis.J Clin Endocrinol Metab. 2010 Apr;95(4):1555-65. doi: 10.1210/jc.2009-1947. Epub 2010 Feb 19. J Clin Endocrinol Metab. 2010. PMID: 20173017 Review.
-
[Bisphosphonate].Nihon Rinsho. 2011 Jul;69(7):1253-7. Nihon Rinsho. 2011. PMID: 21774367 Review. Japanese.
-
Clinical review 1: Bisphosphonate use in childhood osteoporosis.J Clin Endocrinol Metab. 2009 Feb;94(2):400-9. doi: 10.1210/jc.2008-1531. Epub 2008 Nov 25. J Clin Endocrinol Metab. 2009. PMID: 19033370 Review.
-
[Bisphosphonate treatment of osteoporosis and other skeletal diseases].Tidsskr Nor Laegeforen. 2011 Feb 4;131(3):244-7. doi: 10.4045/tidsskr.09.0470. Tidsskr Nor Laegeforen. 2011. PMID: 21304573 Review. Norwegian.
-
Benefits and risks of bisphosphonate therapy for osteoporosis.J Clin Endocrinol Metab. 2012 Jul;97(7):2272-82. doi: 10.1210/jc.2012-1027. Epub 2012 Apr 20. J Clin Endocrinol Metab. 2012. PMID: 22523337 Review.
Cited by
-
Pediatric Osteoporosis: Diagnosis and Treatment Considerations.Drugs. 2017 Apr;77(6):679-695. doi: 10.1007/s40265-017-0715-3. Drugs. 2017. PMID: 28271302 Review.
-
Medication-Related Osteonecrosis of the Jaws (MRONJ) in Children and Young Patients-A Systematic Review.J Clin Med. 2023 Feb 10;12(4):1416. doi: 10.3390/jcm12041416. J Clin Med. 2023. PMID: 36835951 Free PMC article. Review.
-
Use of burosumab in McCune Albright syndrome: case report and review of literature in mosaic disorders with FGF23 overproduction.Front Endocrinol (Lausanne). 2025 May 26;16:1577734. doi: 10.3389/fendo.2025.1577734. eCollection 2025. Front Endocrinol (Lausanne). 2025. PMID: 40491596 Free PMC article. Review.
-
Hypocalcemia following Neridronate Administration in Pediatric Patients with Osteogenesis Imperfecta: A Prospective Observational Study.J Pediatr Genet. 2020 Jun;9(2):93-100. doi: 10.1055/s-0039-1700972. Epub 2020 Jan 6. J Pediatr Genet. 2020. PMID: 32341811 Free PMC article.
-
Bisphosphonates: from softening water to treating PXE.Cell Cycle. 2015;14(9):1354-5. doi: 10.1080/15384101.2015.1024585. Cell Cycle. 2015. PMID: 25894689 Free PMC article. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical